Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012
Combination versus monotherapy for nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 50-55 Year: 2007
Efficacy of α-tocoferol in the treatment of patients with pneumonia Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008
Changes in empirical initial antibiotic therapy in community-acquired pneumonia: assessment of clinical failure versus discordant therapy Source: Eur Respir J 2006; 28: Suppl. 50, 736s Year: 2006
Comparison of different models of azithromycin treatment of patients with no severe community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 166s Year: 2006
Therapeutic regimens in community acquired pneumonia (CAP): association with patients characteristics and outcomes Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008
Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018
Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP) Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008
Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Cost-efficacy analysis of cefixime switch therapy in the treatment of community acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006
A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015
The usage of laferon in treatment of patients with community acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 675s Year: 2007
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Source: Eur Respir J 2003; 21: 135-143 Year: 2003
Macrolides (alone or in combination) should be used as first-line empirical therapy of community-acquired pneumonia in children: myth or maxim? Source: Breathe, 17 (3) 210056; 10.1183/20734735.0056-2021 Year: 2021
Efficacy of using special software “Optimization of medication choice for treatment of patient with comorbidity” (SS) for management of patients with community-acquired pneumonia (CAP) and cardiovascular disease Source: International Congress 2019 – M-health/e-health I Year: 2019
Efficacy of traditional and combined therapy in patients with sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 234s Year: 2003
Lack of clinically relevant differences between combination therapy and monotherapy in COPD Source: Eur Respir J 2014; 43: 1204 Year: 2014
Lack of clinically relevant differences between combination therapy and monotherapy in COPD Source: Eur Respir J 2014; 43: 1204-1205 Year: 2014
Efficacy and safety of stepwise therapy in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 377s Year: 2006